Rosetta Genomics Ltd. (ROSG) Release: Data Presented at American Society of Clinical Oncology 2010 by M. D. Anderson Cancer Center Researchers Demonstrate the ability of miRvie(TM) mets to Identify the Most Likely Origin of Metastases in Cancer of Unknown Primary  
6/7/2010 2:05:48 PM

REHOVOT, Israel & PHILADELPHIA--(BUSINESS WIRE)--Rosetta Genomics, Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based molecular diagnostic tests, announces new, interim data from an ongoing prospective study conducted in collaboration with researchers from the University of Texas, M. D. Anderson Comprehensive Cancer Center (MDACC), and presented at ASCO 2010. The ongoing study is designed to examine the ability of miRview mets to identify the most likely primary origin of metastases in patients with cancer of unknown primary (CUP). This was achieved by correlating the predicted primary origin assigned by miRview mets with the comprehensive diagnostic work-up conducted at MDACC, which included surgical pathology, laboratory tests, imaging and a treatment-response follow-up.